Alkem launches pertuzumab biosimilar for breast cancer in India
The company has introduced Pertuza injection 420mg/14mL, a pertuzumab biosimilar, for the treatment of HER2-positive breast cancer, the drug firm said in a statement
 "Injections, Injection syringe")
"Oncology is a priority area for Alkem, and our efforts are focused on developing treatment options that combine scientific excellence with wider access. The launch of Pertuza reflects this commitment and further strengthens our oncology portfolio," Alkem CEO Vikas Gupta said. (Representative Photo: Bloomberg)
Listen to This Article
Alkem Laboratories on Monday said it has launched a biosimilar product in India for the treatment of breast cancer.
The company has introduced Pertuza injection 420mg/14mL, a pertuzumab biosimilar, for the treatment of HER2-positive breast cancer, the drug firm said in a statement.
Alkem's Pertuza is an affordable, indigenously-developed and manufactured biosimilar of pertuzumab, it added.
"Oncology is a priority area for Alkem, and our efforts are focused on developing treatment options that combine scientific excellence with wider access. The launch of Pertuza reflects this commitment and further strengthens our oncology portfolio," Alkem CEO Vikas Gupta said.
Shares of the company on Monday ended 0.69 per cent down at Rs 5,496 apiece on BSE.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
More From This Section
 "Adani Group")
 "Energy, Solar energy, Wind Energy")
 "real estate, realty firms")
 "Manish Prasad")
Don't miss the most important news and views of the day. Get them on our Telegram channel
First Published: Sep 22 2025 | 8:07 PM IST